NCT02799121已完成4 期
A Feasibility Study of the ReGenerCell™ Autologous Cell Harvesting Device for Diabetic Foot Ulcers
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 5
- 主要终点
- Complete Wound Closure
研究概览
简要总结
This prospective case series is to gain additional clinical experience in the treatment of diabetic foot ulcers, by documenting and relating patient history (including baseline wound characteristics) and clinical outcomes (incidence of healing, rate of healing, and patient and physician satisfaction) in a group of study participants for whom the ReGenerCell™ Autologous Cell Harvesting Device (ReGenerCell™) is used in combination with conventional therapy for the closure of diabetic foot ulcers (DFUs). Participants will receive ReGenerCell™ treatment in addition to standard care (debridement, cleansing, dressings, offloading).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient has stable diabetes mellitus according to investigators clinical judgement
- •Diabetic foot Ulcer
- •Groups 1 and 2: Ulcer surface area between 3 cm2 and 100 cm2 (inclusive)
- •Group 1: 12-24 weeks in duration, no directly visible tendon or bone (University of Texas Ulcer grade 1A)
- •Group 2: >3 weeks in duration, University of Texas Ulcer grade 1B, 2A, 2B, 3A, 3B
- •No superficial skin infection (of the ulcer area) requiring intervention
- •Adequate offloading and compliance must be achievable
- •The patient is 18 years of age or older
- •The patient is willing to complete all follow-up evaluations required by the study protocol
- •The patient is able to abstain from any other non-standard treatment of the ulcer for the duration of the study, unless medically necessary
- •The patient agrees to abstain from enrolment in any other interventional clinical trial for the duration of the study
- •The patient is able to read and understand instructions and give voluntary written informed consent
- •The patient is able and willing to follow the protocol
排除标准
- •Patients requiring intervention for Peripheral Arterial Disease (PAD) will be excluded from this study
- •Severe Peripheral Arterial Disease that is not reconstructible
- •Pregnant/lactating females (self-reported or tested, per institutional requirements
- •Use of non-inert dressings (silver, honey etc.) during the past 10 days
- •Subjects who have evidence of connective tissue disorders (e.g. vasculitis or rheumatoid arthritis) under active treatment
- •The patient is known to have a pre-existing active condition that may interfere with wound healing, e.g. malignancy, autoimmune disease, immunocompromised blood borne diseases, the patient has AIDS, is HIV- or Hepatitis-C positive, or currently has a severe dermatological disorder (e.g. severe psoriasis, epidermolysis bullosa, pyoderma gangrenosum).
- •The patient is taking, or has taken in the past 60 days, >10mg of corticosteroids per day.
- •The patient has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives
- •The patient has a known hypersensitivity to trypsin or Compound Sodium Lactate solution.
- •The patient is a vulnerable or protected adult
- •The patient is unable to follow the protocol
- •The patient is unable to provide consent
结局指标
主要结局
Complete Wound Closure
时间窗: 26 Weeks
100% Re-epithelialisation of wound
次要结局
- Neuro-QoL(26 Weeks)
- Wound size(26 Weeks)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
不适用
Bone Marrow Autotransplantation in Type 1 DiabetesType 1 Diabetes MellitusNCT00821899Hospital Clinic of Barcelona3
已完成
不适用
Managing Diabetes to Gain Opportunities for a More Active LifeDiabetes Mellitus, Type 2NCT03692208University of Chicago110
已完成
不适用
The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 DiabetesType 2 Diabetes MellitusNCT03552523Massachusetts General Hospital16
Unknown
3 期
Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver CirrhosisEnd Stage Liver DiseaseNCT03109236National University Hospital, Singapore66
已完成
不适用
Peers EXCEL Trial to Improve Glycemic ControlType 2 DiabetesNCT05527847University of Wisconsin, Madison14